Psychiatry & Neurology Doctors in Kinston, NC Accepting Medicare

7 Psychiatry & Neurology doctors found. Showing 1 - 7

Dr. Gening Zhu, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 2901 N Herritage St, Kinston, NC 28501 Phone: 252-233-2383    Fax: 252-523-3148

Mrs. Joanna Wolicki-shannon, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1305 North Queen Street, Kinston, NC 28501 Phone: 252-523-2781    Fax: 252-523-2711

Dr. Bryan D Spader, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: Eastpointe Kinston, 2901 N Heritage St, Kinston, NC 28501 Phone: 252-233-2260    Fax: 252-523-3262

Mr. Walter Daniel Shannon Jr., M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1305 North Queen Street, Kinston, NC 28501 Phone: 252-523-2781    Fax: 252-523-2711

Manasi Gahlot, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 701 Doctors Dr, Suite G, Kinston, NC 28501 Phone: 252-522-4446    Fax: 252-522-4484

Dr. Marion Edward Wright Jr., MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 107 S Queen St, Kinston, NC 28501 Phone: 252-522-9800    Fax: 252-523-9790

Dr. Rickie Wade Ellis, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 107 S Queen St, Kinston, NC 28501 Phone: 252-522-9800    Fax: 252-523-9790

News Archive

Accretive Health third quarter net services revenue increases 38% to $218.9 million

Accretive Health, Inc., a leading provider of comprehensive end-to-end healthcare revenue cycle management services and population health management services infrastructure, today announced financial results for the third quarter ended September 30, 2011.

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

Subclinical inflammation predicts macular disease

Levels of high-sensitivity C-reactive protein predict the risk for age-related macular degeneration and diabetic macular edema, show results of two independent studies published in JAMA Ophthalmology.

Inovio awarded U.S. DOD grant to advance non-invasive surface electroporation delivery device

Inovio Pharmaceuticals, Inc. announced today it has received a U.S. Department of Defense Small Business Innovation Research Grant to advance the development of a low-cost, non-invasive surface electroporation (EP) delivery device and test its utility in combination with Inovio's novel synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza.

HTA acquires Smyth Professional Building in Maryland

Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the completed acquisition of a medical office building, known as the Smyth Professional Building, located in Baltimore, Maryland for approximately $11,250,000.

Read more Medical News

› Verified 4 days ago